228 related articles for article (PubMed ID: 35384800)
1. Immunosuppression, Compliance, and Tolerance After Orthotopic Liver Transplantation: State of the Art.
Zorzetti N; Lauro A; Khouzam S; Marino IR
Exp Clin Transplant; 2022 Mar; 20(Suppl 1):3-9. PubMed ID: 35384800
[TBL] [Abstract][Full Text] [Related]
2. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
3. From immunosuppression to tolerance.
Adams DH; Sanchez-Fueyo A; Samuel D
J Hepatol; 2015 Apr; 62(1 Suppl):S170-85. PubMed ID: 25920086
[TBL] [Abstract][Full Text] [Related]
4. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
[TBL] [Abstract][Full Text] [Related]
5. Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors.
Barbier L; Garcia S; Cros J; Borentain P; Botta-Fridlund D; Paradis V; Le Treut YP; Hardwigsen J
J Hepatol; 2013 Dec; 59(6):1223-30. PubMed ID: 23933266
[TBL] [Abstract][Full Text] [Related]
6. Limitations of current liver transplant immunosuppressive regimens: renal considerations.
Zhang W; Fung J
Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):27-32. PubMed ID: 28119255
[TBL] [Abstract][Full Text] [Related]
7. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
[TBL] [Abstract][Full Text] [Related]
8. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.
Penninga L; Wettergren A; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2012 Mar; (3):CD008852. PubMed ID: 22419339
[TBL] [Abstract][Full Text] [Related]
10. Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients.
Meszaros M; Dubois V; Congy-Jolivet N; Hamada S; Thevenin C; Faure S; Boillot O; Kamar N; Pageaux GP; Del Bello A; Dumortier J
Liver Int; 2022 May; 42(5):1132-1143. PubMed ID: 35184373
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
12. Current concepts and perspectives of immunosuppression in organ transplantation.
Scherer MN; Banas B; Mantouvalou K; Schnitzbauer A; Obed A; Krämer BK; Schlitt HJ
Langenbecks Arch Surg; 2007 Sep; 392(5):511-23. PubMed ID: 17450373
[TBL] [Abstract][Full Text] [Related]
13. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
Nogueras López F; Abellan Alfocea P; Ortega Suazo EJ; López Garrido MA; Becerra Massare A; Gila Medina AM; Redondo Cerezo E; Espinosa Aguilar MD
Transplant Proc; 2020 Mar; 52(2):556-558. PubMed ID: 32035673
[TBL] [Abstract][Full Text] [Related]
14. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
15. Medical Aspects of mTOR Inhibition in Kidney Transplantation.
Cuadrado-Payán E; Diekmann F; Cucchiari D
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887051
[TBL] [Abstract][Full Text] [Related]
16.
Manzia TM; Angelico R; Gazia C; Lenci I; Milana M; Ademoyero OT; Pedini D; Toti L; Spada M; Tisone G; Baiocchi L
World J Gastroenterol; 2019 Sep; 25(35):5356-5375. PubMed ID: 31558879
[TBL] [Abstract][Full Text] [Related]
17. Calcineurin inhibitors in renal transplantation: what is the best option?
Tanabe K
Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression in liver transplant.
Di Maira T; Little EC; Berenguer M
Best Pract Res Clin Gastroenterol; 2020; 46-47():101681. PubMed ID: 33158467
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation.
Wong TC; Lo CM; Fung JY
Expert Opin Emerg Drugs; 2017 Jun; 22(2):123-136. PubMed ID: 28503959
[TBL] [Abstract][Full Text] [Related]
20. Lower tacrolimus trough levels in the late period after living donor liver transplantation contribute to improvements in long-term clinical outcomes.
Geng L; Wang LD; Huang JJ; Shen T; Wang ZY; Lin BY; Ye YF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):204-209. PubMed ID: 29807766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
